Terazosin
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Terazosin
- Terazosin: From Alpha-1 Blocker Use (Hypertension/BPH) to Hypotrichosis Simplex of the Scalp
Terazosin: From Alpha-1 Blocker Use (Hypertension/BPH) to Hypotrichosis Simplex of the Scalp
One-Sentence Summary
Terazosin is an oral alpha-1 adrenergic blocker, generally used for hypertension and benign prostatic hyperplasia. The TxGNN model predicts it may be effective for hypotrichosis simplex of the scalp, but this is a model prediction only, with 0 clinical trials and 0 publications supporting it.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not listed in the US license records; generally hypertension and benign prostatic hyperplasia (general pharmacological knowledge) |
| Predicted New Indication | Hypotrichosis simplex of the scalp |
| TxGNN Prediction Score | 99.97% |
| Evidence Level | L5 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 20 (the listed records are generic ANDAs) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the Evidence Pack. Based on general pharmacology, terazosin is an alpha-1 adrenergic antagonist that relaxes vascular and prostatic smooth muscle.
The link to the predicted indication is weak. Hypotrichosis simplex is a monogenic hair-follicle disorder, and a vasodilator or alpha-1 antagonist is unlikely to address the underlying defect. The high score most likely reflects knowledge-graph proximity to other hair-loss conditions rather than a validated biological effect.
The most an analyst could suggest is an indirect effect through improved scalp microcirculation, as discussed for some vasoactive drugs. Alpha-1 blockade has not been shown to promote hair growth.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
The approved_indication_text field is empty for all listed records.
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ANDA075317 | Terazosin (Jubilant Cadista) | Capsule | Not listed |
| ANDA074823 | Terazosin Hydrochloride (Aphena Pharma Solutions) | Capsule | Not listed |
| ANDA075317 | Terazosin (Aphena Pharma Solutions) | Capsule | Not listed |
| ANDA075667 | Terazosin (Bionpharma) | Capsule | Not listed |
| ANDA075614 | Terazosin (Chartwell RX) | Capsule | Not listed |
Only the oral capsule route is available (5 of 20 authorizations shown).
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: This is a pure model prediction (L5) with no trials, no literature, and no plausible mechanism for a monogenic hair-follicle disorder. Nothing supports moving forward on this indication.
To proceed, the following is needed:
- The US package insert warnings and contraindications, which are currently missing and block safety screening
- Mechanism of action data (for example, from DrugBank)
- Any preclinical evidence of a hair-follicle effect of alpha-1 blockade
Other predictions for this drug: The pack’s other predicted indications look more credible than this top-ranked one. Raynaud disease (a 1997 clinical study) and migraine disorder (a 1994 small open study and a 1997 review) are both rated L3 and flagged as “Research Question”. Both are old, small, and uncontrolled, so a modern controlled trial would be needed, with attention to hypotension and dizziness. Consider prioritizing those two over the hair-related predictions.
This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any use.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.